Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma patients treated with R-CHOP
- 1 August 2009
- journal article
- Published by Elsevier BV in Laboratory Investigation
- Vol. 22 (8), 1094-1101
- https://doi.org/10.1038/modpathol.2009.73
Abstract
No abstract availableThis publication has 30 references indexed in Scilit:
- Stromal Gene Signatures in Large-B-Cell LymphomasThe New England Journal of Medicine, 2008
- Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOPBlood, 2008
- The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximabLeukemia, 2008
- Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) studyThe Lancet Oncology, 2008
- Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)The Lancet Oncology, 2008
- Introduction of Combined CHOP Plus Rituximab Therapy Dramatically Improved Outcome of Diffuse Large B-Cell Lymphoma in British ColumbiaJournal of Clinical Oncology, 2005
- Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarrayBlood, 2004
- The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell LymphomaThe New England Journal of Medicine, 2002
- CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell LymphomaThe New England Journal of Medicine, 2002
- Distinct types of diffuse large B-cell lymphoma identified by gene expression profilingNature, 2000